Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

Ultragenyx Pharmaceutical is supported by a solid commercial base with four marketed drugs, led by Crysvita, which has $2B+ global sales potential and contributes about 1/4 of profits through the KHK collaboration, while Dojolvi and Mepsevii add diversification in rare-disease care. The outlook is further strengthened by a deep pipeline with four candidates in clinical development across at least six indications, including DTX401, DTX301, UX111, and UX701, plus near-term catalysts such as pivotal and Phase 3 readouts in 2026 and 2027. Recent approval also delivered a PRV that could help generate about $400M in non-dilutive capital, and planned expense reductions should improve valuation recognition despite the company’s high spend profile.

Ultragenyx Pharmaceutical is facing a weaker fundamental outlook because the ASPIRE Phase 3 failure for GTX-102 removed a major long-term growth driver, with no separation versus control on either the primary or key secondary endpoint. The loss of an estimated $1.7B in peak GTX-102 revenue, combined with a conservative FY30 breakeven view and a planned reduction in OpEx, underscores how much of the prior growth case depended on a now-discredited asset. Beyond this setback, the company still faces lower-than-expected base-business revenue risk, intense competition, reimbursement pressure, and heightened regulatory scrutiny in gene therapy, leaving investors reliant on commercial execution from Crysvita, Dojolvi, Mepsevii, and UX111.